课题基金 / 基金详情

The Th17 Master Regulator RORC2 as a New Target for HIV Immune Therapy and Cure Strategy

The Th17 Master Regulator RORC2 as a New Target for HIV Immune Therapy and Cure Strategy
Th17 主调节因子 RORC2 作为 HIV 免疫治疗和治愈策略的新靶点
批准号：
444098
负责人：
Ancuta Petronela
金额：
$64.65万
依托单位：
Centre hospitalier de l'Universit de Montral (CHUM)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
未结题
起止时间：
2021-04-01 至 2025-04-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=444098&lang=en
关键词：
Antiretroviral Therapy Chromatin Ip Confocal Microscopy/Image Stream Crispr Cas9 Flow Cytometry Sorting Hiv-1 Humanized Mice Rna Sequencing Rorc2 Th17 Cells

项目摘要

项目成果

Ancuta Petronela的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Combined antiretroviral therapies (ART) are highly efficient in controlling HIV replication at undetectable plasma levels, therefore improving the life quality of people living with HIV (PLWH). However, ART does not eradicate HIV and treatment interruptio
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Finding the Perfect Time to Hunt for HIV: A Tale of 36 Hours at the CHUM
Identification of Aryl Hydrocarbon Receptor as a Novel Druggable Modulator of HIV-1 Latency
The Th17 Master Regulator RORC2 as a New Target for HIV Immune Therapy and Cure Strategy
Targeting mTOR to restore mucosal immunity toward remission in HIV-infected individuals
海外基金